Enliven Therapeutics, Inc.

ELVN - CIK 0001672619

Market cap$2.20 B

Rank#2035

SEC filings750

Enliven Therapeutics, Inc. trades as ELVN and has a market capitalization of $2.20 B, making it the #2035 largest US-listed company by market value. This page tracks Enliven Therapeutics, Inc. through 750 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Net income (latest FY)-$103.70MFY 2025

Operating cash flow (latest FY)-$70.30MFY 2025

Total assets (latest FY)$476.17MFY 2025

Financial performance

ELVN annual net incomeView details

ELVN operating cash flowView details

Key statistics

Market cap: $2.20 B
Share price (derived)market cap / shares outstanding: $36.06
EPS (diluted)FY 2025: $-1.83
Shares outstandingas of 2026-04-28: 0.06B
Total equityas of 2026-03-31: $453.37M
Return on equity: -22.9%
Cash & equivalentsas of 2026-03-31: $132.18M
Current ratioas of 2026-03-31: 40.32

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-20
Insider sale notice	144	2026-05-18
SCHEDULE 13G/A	-	2026-05-15
SCHEDULE 13G/A	-	2026-05-15
SCHEDULE 13G/A	-	2026-05-15
SCHEDULE 13G/A	-	2026-05-15
SCHEDULE 13G/A	-	2026-05-15
SCHEDULE 13G/A	-	2026-05-15

Browse the full filing history (750 filings)

Recent press releases

Enliven Therapeutics to Present at Upcoming Investor Conferences2026-05-21
Enliven Therapeutics to Present at Upcoming Investor Conferences | Enliven Therapeutics
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML2026-05-12
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML | Enliven Therapeutics
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update2026-05-07
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | Enliven Therapeutics
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update2026-03-03
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update | Enliven Therapeutics
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference2026-02-25
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference | Enliven Therapeutics

Similar companies

The largest companies sharing Enliven Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T ELVN vs LLY

JNJJohnson & Johnson$573.98 B ELVN vs JNJ

ABBVAbbVie Inc.$399.47 B ELVN vs ABBV

MRKMerck & Co., Inc.$293.16 B ELVN vs MRK

AZNAstraZeneca PLC$286.27 B ELVN vs AZN

Frequently asked questions

What is Enliven Therapeutics, Inc.'s market cap?

Enliven Therapeutics, Inc. (ELVN) has a market capitalization of $2.20 B as of 2026-06-10, ranking #2035 among US-listed companies.

Is Enliven Therapeutics, Inc. profitable?

In its latest fiscal year Enliven Therapeutics, Inc. reported a net loss of $103.70M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.